Curi Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Curi Bio - overview
Established
2015
Location
Seattle, WA, US
Primary Industry
Biotechnology
About
Founded in 2015 by CEO Nicholas Geisse and Elliot Fisher and based in Washington, US, Curi Bio, Inc. , formerly NanoSurface Biomedical develops integrating human cells, systems, and data. In December 2025, Curi Bio, Inc. raised USD 10 million in series B funding led by new investor DreamCIS.
Curi Bio, Inc. provides a discovery platform that combines human stem cells, systems, and data in discovering new medicines. The firm also provides technologies and products that include NanoSurface Plates for structural maturation, Cytostretcher cell-stretching instruments, and Mantarray for 3D tissue contractility analysis, and it specializes in cardiac, musculoskeletal, and neuromuscular models.
Current Investors
Dynamk Capital, UTC Investment, DS Asset Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics, Pharmaceutical Research & Development
Website
www.curibio.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.